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Abstract
Background: Krabbe disease is a rare neurodegenerative genetic disorder caused by deficiency of galactocerebrosidase.
Patients with the infantile form of Krabbe disease can be treated at a presymptomatic stage with human stem cell
transplantation which improves survival and clinical outcomes. However, without a family history, most cases of infantile
Krabbe disease present after onset of symptoms and are ineligible for transplantation. In 2006, New York began screening
newborns for Krabbe disease to identify presymptomatic cases. To ensure that those identified with infantile disease
received timely treatment, New York public health and medical systems took steps to accurately diagnose and rapidly
refer infants for human stem cell transplantation within the first few weeks of life. After 11 years of active screening in
New York and the introduction of Krabbe disease newborn screening in other states, new information has been gained
which can inform the design of newborn screening programs to improve infantile Krabbe disease outcomes.
Findings: Recent information relevant to Krabbe disease screening, diagnosis, and treatment were assessed by a diverse
group of public health, medical, and advocacy professionals. Outcomes after newborn screening may improve
if treatment for infantile disease is initiated before 30 days of life. Newer laboratory screening and diagnostic
tools can improve the speed and specificity of diagnosis and help facilitate this early referral. Given the rarity
of Krabbe disease, most recommendations were based on case series or expert opinion.
Conclusion: This report updates recommendations for Krabbe disease newborn screening to improve the timeliness of
diagnosis and treatment of infantile Krabbe disease. In the United States, several states have begun or are considering
Krabbe disease newborn screening. These recommendations can guide public health laboratories on methodologies for
screening and inform clinicians about the need to promptly diagnose and treat infantile Krabbe disease. The timing of
the initial referral after newborn screening, the speed of diagnostic confirmation of infantile disease, and the
transplantation center’s experience and ability to rapidly respond to a suspected patient with newly diagnosed
infantile Krabbe disease are critical for optimal outcomes.
Keywords: Krabbe disease, Newborn screening, Guidelines, Human stem cell transplantation, Infantile Krabbe
disease, Confirmatory testing, Galactocerebrosidase, Lysosomal storage disorder, Psychosine
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Background
Krabbe disease (KD) is an autosomal recessive, neurode-
generative disease caused by deficiency of the lysosomal
enzyme galactocerebrosidase (GALC), which is essential
for myelin turnover [1] and is encoded by the GALC
gene. In the infantile form of KD (IKD), children can
appear normal at birth, but in the first year, usually the
first months, they develop irritability, feeding difficulties,
progressive spasticity, blindness and deafness. Over time,
IKD patients cease to have voluntary movements, and
death occurs in infancy or childhood [2]. Before New
York (NY) instituted newborn screening for KD in 2006
[2], the estimated incidence was thought to be about 1
in 100,000 births [1, 2], with the majority of KD patients
expected to have IKD. The most common GALC muta-
tion seen in IKD patients of European ancestry is a 30-
kb deletion starting at intron 10 (of the 17-exon gene)
and extending beyond the end of the gene. In 2004, Gelb
and colleagues described a high-throughput GALC en-
zyme assay making use of dried blood spots (DBS) [3],
and in 2005, Escolar and colleagues reported that pre-
symptomatic human stem cell transplantation (HSCT)
in IKD resulted in greatly improved outcomes com-
pared to those who were untreated or treated after
symptoms began [4].
Given the potential benefits of HSCT in presymptom-
atic infants with IKD, NY became the first state to
mandate and implement KD-NBS to enable early diag-
nosis and treatment of KD. The experience of the first 8
years of newborn screening has recently been described
[5, 6]. The incidence of IKD in NY was lower than
expected with only five affected infants (including one
sibling pair) identified among nearly two million
screened (1/394,000) [5]. Only four infants ultimately
received HSCT (the family of one infant with IKD ini-
tially refused, but they agreed to HSCT for a later-born
sibling) and in this small cohort, two died and one had
severe developmental delays [6]. The NY experience em-
phasizes the challenges inherent in treating IKD, where
symptoms appear so early and progress so quickly that
HSCT, to be done at a “presymptomatic stage,” needs to
be initiated in the first month of life, and may be, even
then, too late [6].
The NY outcomes were unexpectedly poor given what
was known of the previously reported cohort trans-
planted at Duke University [4] and at other sites [7]
where combined mortality was 10%. For example, only 1
of the 5 infants in NY was referred to a specialized
transplant center in time to have HSCT before 30 days
of age [6]. A recent report of the long-term developmen-
tal outcomes of 18 IKD infants who were transplanted
presymptomatically at less than 2 months of age, showed
that the 10 who were transplanted in the first 4 weeks of
life had better survival and daily function [8]. This
suggests that IKD patients identified by NBS might have
better outcomes if they are transplanted in the first
month of life at a HSCT center experienced with this
disorder.
The challenging timeline needed to improve IKD out-
comes was the impetus for establishing a multi-state and
multi-disciplinary KD-NBS task force (“Task Force”) to
review the literature, share recent experiences and
develop new guidance to improve the speed of IKD diag-
nosis, and initiation of HSCT.
Methods
The Task Force members (including all co-authors) were
drawn from a larger group of public health, medical, and
advocacy professionals who met in person in October
2015 to discuss how IKD outcomes might be improved
after KD-NBS. The Task Force met by phone and in-
person meetings between October 2015 and July 2017 to
discuss the existing evidence, from which consensus rec-
ommendations were developed.
Figure 1 shows a simplified graph of ideal time-points
for KD-NBS, diagnosis of IKD, and referral to HSCT pro-
gram. The graph also shows the key questions (labelled
Q1-Q3 in Fig. 1) being addressed by this Task Force.
Key questions to be addressed (Fig. 1)
Question 1. Newborn Screening Laboratory: Are there
preferred laboratory methods and workflows to ensure
acceptable sensitivity, specificity, and timeliness in iden-
tifying IKD patients?
a. Which methods are recommended as the primary
screening test for IKD in DBS?
b. Is second tier testing (subsequent studies for
additional, more specific disease markers using the
original NBS DBS sample) necessary? If so, which
tests should be considered?
c. How quickly does the laboratory need to report a
positive screening result for IKD?
Question 2. Specialty Care Center (SCC): After the la-
boratory makes a referral, what confirmatory diagnostic
testing should be performed to establish an IKD
diagnosis?
a. What testing is necessary to establish a diagnosis of
IKD?
b. Should ancillary neurodiagnostic tests such as from
cerebrospinal fluid (CSF), magnetic resonance
imaging (MRI), or electromyography, be obtained?
Question 3. Treatment: What criteria should be con-
sidered when referring IKD patients for HSCT?
Kwon et al. Orphanet Journal of Rare Diseases  (2018) 13:30 Page 2 of 10
Sources of Evidence: For the questions above, the Task
Force collected available evidence in the form of 1) relevant
articles identified by literature search of MEDLINE,
EMBASE, and CINAHL databases, and 2) unpublished data
provided by experts which were put in written abstract for-
mat and reviewed by members of the work group. The evi-
dence review procedures were based on the Scottish
Intercollegiate Guidelines Network (SIGN) criteria [9, 10]
used in guideline development for other rare disorders [11,
12]. Relevant articles and data were judged on their evi-
dence quality. Level 1 evidence was based on randomized
controlled trials; 2 on case-control or cohort studies; 3 on
case series or reports; 4 on expert opinion. Recommenda-
tions in response to the questions above were graded A-D
based on evidence quality, with grade A recommendations
based primarily on high-quality level 1 evidence; B on levels
1 and 2 evidence; C on high quality case-control and cohort
studies; and D on biased case-control studies, non-analytic
case series, case reports or expert opinion.
Results
Question 1: Newborn screening for Krabbe disease using
DBS
Initial screening tests
There are several approaches to DBS GALC enzyme
evaluation for KD screening (Table 1). To date, all but
one state program uses tandem mass spectrometry (MS/
MS) based assays, and several programs screen for sev-
eral lysosomal enzymes simultaneously [13–16].
Missouri (MO) is currently employing fluorometry to
screen for GALC activity and four other lysosomal en-
zymes [17]. Regardless of the methods, measures of
GALC activity alone do not have sufficient specificity;
significant overlap exists between GALC activities
observed in KD patients, GALC mutation carriers and
healthy individuals with genotypes conferring in vitro
GALC deficiency (pseudo-deficiency). For this reason,
KD-NBS programs will typically employ additional tiers
of screening if DBS GALC activity is reduced (Table 2).
Second tier screening tests
The strategy for additional testing of samples with low
GALC activity in NY has been reported [5, 13]. First,
testing of other lysosomal enzymes is performed as a ref-
erence to assess sample quality. If there is still concern,
full Sanger sequencing of all exons and all exon/intron
boundaries of the GALC gene, as well as special PCR
analysis, “GAP-PCR,” to detect the common 30kbDel
serves as the 2nd tier test. This has improved specificity
so that infants with low GALC activity and known be-
nign variants are not referred for follow-up [5]. The
genotype information can provide additional diagnostic
Table 1 DBS based GALC enzyme assays for KD-NBS
Assay
Platform
MS/MS MS/MS Fluorometry
Marker GALC activity GALC activity GALC activity
Substrate Synthetic analog of
galactosylceramide
containing a C8-
fatty acyl chain;
after incubation
with GALC, releases
novel ceramide
Synthetic analog of
galactosylceramide
containing a C7-
fatty acyl chain;
after incubation
with GALC, releases
novel ceramide
Artificial
fluorogenic
compound; after
incubation with
GALC, releases 4-
MU analog that
is measured
fluorometrically
States
using
assay
-* IL, KY, NY, OH MO
Reference [3, 39] [3, 16, 40] [17]
*Reagents have been discontinued
Fig. 1 Recommended flow of KD-NBS with optimal times of events, such as receipt of specimen and referral to specialty care center, indicated by
number of days of life. The labels, “Q1-Q3,” highlight the key questions 1-3 (see text) being addressed in this evidence review. DOL is infant age
in days of life. Additional figure abbreviations: NBS = newborn screening; HSCT = human stem cell transplantation
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and prognostic information before the infant is referred
and can be valuable to the specialists charged with
evaluating, providing counselling, and obtaining con-
firmatory testing. However, few programs have the abil-
ity to perform this level of comprehensive molecular
genetic testing and genotypes of uncertain significance
are frequently encountered, as seen in the ethnically
diverse NY population [5, 6].
The MO NBS program has chosen to test only for
the pathogenic 30kbDel mutation in those whose ini-
tial DBS GALC activity falls below a predetermined
threshold. To further reduce the likelihood of false
negative results, MO uses a second GALC activity
value in their screening which is lower than the first,
such that all infants falling below this value are re-
ferred to specialty care centers even if the 30kbDel is
not detected [17].
Other strategies incorporate measurement of psycho-
sine using liquid chromatography MS/MS as a 2nd tier
test [16]. Psychosine is one of several substrates of the
GALC enzyme and its accumulation may cause or con-
tribute to the demyelination and neurodegeneration in
KD patients. There has been accumulating evidence
that measurement of psychosine concentrations in DBS
correlates with clinical disease in IKD patients. Psycho-
sine is normal in controls or those with benign GALC
variants, but elevated in the newborn DBS of KD pa-
tients with infantile and symptomatic late onset disease
[18–20]. In NY, all confirmed IKD patients that were
referred for HSCT had highly elevated psychosine
values (Table 3), and psychosine appears to be specific
for severe symptomatic KD. In NY, the NBS laboratory
has recently added psychosine testing as another sec-
ond tier test used in conjunction with full Sanger
sequencing and 30kbDel detection. NY state’s current
approach may be more than necessary for KD-NBS,
since the available data from those known to have KD
suggest that psychosine appears to be at least as good
as standard molecular GALC testing in determining the
likelihood of IKD [16, 19].
In Kentucky (KY), the NBS program includes KD and
two other lysosomal storage diseases (Pompe disease
and Mucopolysaccharidosis type I), with three other
lysosomal enzymes being tested as reference enzymes
[16]. Measuring activity with multiple lysosomal en-
zymes can increase clinical specificity, especially when
these values are used with recently developed postanaly-
tical tools that use variables, such as age at sample
collection, birth weight and gestational age [15, 21, 22].
In KY, 2nd tier testing is employed when postanalytical
multivariate analysis of the initial DBS LSD enzyme ac-
tivities are abnormal. The 2nd tier tests include both the
measurement of psychosine and testing for the 30kbDel.
Full GALC sequencing is also performed but only when
the post-analytical score is highly suggestive of KD,
psychosine is normal, and one copy of 30kbDel is
detected. A repeat DBS sample is requested when the
post-analytical score is highly suggestive of KD but psy-
chosine is normal and the 30kbDel is not identified [16].
This approach can efficiently and accurately identify
newborns with IKD when psychosine is elevated and/or
there is 30kbDel homozygosity. Assuming samples are
collected on the 2nd day of life and arrive at the NBS la-
boratory on the following day, this approach allows
reporting of abnormal KD-NBS results by the 5th day of
life, the recommended age for reporting of abnormal re-
sults for critical NBS conditions [23, 24]. When psycho-
sine is normal and only one copy of 30kbDel is present,
GALC sequencing of KY newborns is performed in a less
emergent fashion to rule out later onset KD variants.
A recent case of IKD diagnosed by NBS in KY [16]
highlights the value of using psychosine as a second tier
test. In this infant, GALC activity was reduced and psy-
chosine was elevated (61 nmol/L; abnormal > 10 nmol/
L), prompting expedited referral to a transplant center
on the 6th day of life followed by HSCT on the 24th day
Table 2 Second tier testing methods in KD NBS
Test
Method
Rationale Advantages Disadvantages
30 kb
deletion
testing
Known pathogenic mutation, common
in IKD patients
Low complexity, rapid assay.
When found homozygous indicates IKD.
Rare mutation, whose presence is more
likely to indicate carrier status (i.e. “false
positive”) and where the absence will still
not avoid possible IKD (“false negative”)
Psychosine
testing
Appears to be associated with active
disease in KD patients
Rapid test that when elevated indicates IKD. Requires MS/MS equipment with higher
sensitivity than that typically used in NBS
labs but testing can be regionalized while
still ensuring rapid turnaround time.
GALC
Genotyping
With 30kbDel, it is traditionally considered
the “gold standard” 2nd tier testing in KD-
NBS, but there may still be GALC deletions
missed, leading to false negative results.
Can identify those infants at highest risk
for IKD. Provides some reassurance to
those who are carriers, have only enzyme
lowering polymorphisms, or known “mild”
mutations.
Instrumentation and expertise required are
beyond the capabilities of most NBS labs.
Many GALC mutations identified through
KD-NBS are of uncertain clinical significance.
Database of all known KD genotypes not
available to support genotype interpretations.
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of life. This infant’s GALC genotyping showed only one
pathogenic mutation on standard sequencing and only
with further investigation was a novel deletion detected
by using comparative genomic hybridization array test-
ing. While the NY NBS laboratory would have identified
the deletion, not all screening laboratories have this cap-
ability, and the fact that the genotype had not been
observed in known IKD patients and in the absence of
psychosine measurement, follow up would likely have
led to a later transplant initiation. This case suggests an
advantage of psychosine measurement over even sophis-
ticated molecular genetic 2nd tier tests for IKD.
Addressing Question 1: Are there preferred labora-
tory methods and workflows to ensure acceptable
sensitivity, specificity, and timeliness in identifying
IKD patients?
1a. Recommendation: Both MS/MS or fluorometric
methods of measuring GALC activity can be used as the
primary screen for KD, but neither is sufficiently specific
for KD, let alone IKD, to be used alone. (Note: this rec-
ommendation was not graded because methodologies
employed in NBS laboratories are subject to laboratory
quality standards and regulations).
1b. Recommendation: Second tier testing should be
done to improve the specificity of screening and the
speed in identifying IKD (Table 2). Once a sample is
flagged because of an abnormal primary screen, the test
that has the highest likelihood of identifying IKD cases
using DBS are psychosine analysis with or without sub-
sequent comprehensive molecular genetic analysis of the
GALC gene. (Grade C recommendation).
1c. Recommendation: IKD can progress rapidly and
must be considered a time-critical condition similar to
galactosemia [23, 24]. It is likely that IKD outcomes are
better when potential IKD cases are identified early by
second tier testing and then referred to SCC’s by the 5-
7th day of life (Fig. 1). Depending on the second tier
tests chosen, urgent referrals may be initiated if psycho-
sine levels are elevated or if there is a 30kbDel. SCC
medical specialists should promptly see these potential
IKD cases and have procedures in place for rapid referral
to HSCT centers for further evaluation and treatment
(see below, especially responses to Questions 2b and 3).
(Grade D evidence.)
Of note, these guidelines are meant to ensure more
rapid referral of potential IKD cases. The majority of
those newborns with out-of-range results on first tier
testing will NOT have IKD, but may be at risk for later
onset forms of KD. The screening and follow-up proto-
cols in these patients are not “time-critical” and are be-
yond the scope of this review.
Question 2: Confirmatory diagnostic testing of newborns
referred after abnormal KD-NBS
There are two diagnostic tests commonly used when
infants are referred to specialty care centers for con-
firmatory testing:
a. Leukocyte GALC enzyme activity: When NYS began
KD-NBS, leukocyte GALC activity, as performed in
the Thomas Jefferson Lysosomal Diseases Testing
Laboratory directed by Dr. David Wenger, was used
as a confirmatory diagnostic assay and low GALC
enzyme activity (previously set at ≤0.15 nmol/h/mg
protein [2]), from this laboratory was thought to be
predictive of who would develop IKD. These infants
were categorized as at “high risk” for developing
IKD. All 5 IKD patients identified in NYS were in
this high-risk category; however, another 8 infants
were also in this “high risk” group but they had
Table 3 Summary of previously reported data from NYa comparing IKD infants’ diagnostic results and outcomes to the 8 considered
at high risk to develop KD (but who are asymptomatic to date)
Patienta GALC mutations
(simplified, allele1//allele2)a
WBC GALCa
(nmol/h/mg)
psychosineb
(nmol/L)
Age at
HSCTa
HSCT
Centerc
Outcomea
IKD 1 30kbDel//p.I546T +
p.X670Qext*42
0.01 28.0 32 days A Alive, significant delays but
interactive
2 30kbDel//30kbDel 0.05 32.2 31 days A Death
3 30kbDel//30kbDel 0.02 38.1 refused – Death
4 30kbDel// p.G360Dfs*2 0.12 60 41 days B Alive, severe delays, minimally
interactive
5 30kbDel//30kbDel 0.05 53.1 24 days B Death
High risk for
KDa
N = 8 Bi-allelic pathogenic GALC
mutations
Range:
0.03-0.12
Range:
0.21-2.7
Currently, all continue to do well and have had no
symptoms requiring additional referrals (follow-up
ranging from 1 to 9 years, J. Orsini, personal
communication)
aSee articles on the NY state experience with KD NBS [5, 6] for more detailed information
bPsychosine values reported separately by Escolar et al. [20]; assignment of psychosine values to appropriate infant performed by J. Orsini
cHSCT Center: “A” centers have 5 or more years or experience with HSCT in young children with inherited metabolic conditions, and they have transplanted at
least one patient with presymptomatic IKD in 5 years. Other HSCT programs are labelled “B”
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more reassuring GALC genotypes and – as deter-
mined retrospectively - psychosine was not elevated
(Table 3) [18, 20]. All 8, at the time of publication,
appear to be developing normally [5, 6]. Therefore,
leukocyte GALC enzyme activity alone is not specific
enough to identify IKD. More sensitive GALC activ-
ity assays have been proposed to better discriminate
very low GALC activity indicative of IKD [25]. Until
such assays become clinically available, psychosine
testing in blood (see above) may be useful in the
confirmatory testing phase after an abnormal NBS
result [19, 20].
b. GALC genotyping: The NY KD-NBS experience sug-
gests that GALC genotype can be useful in identify-
ing those infants likely to develop IKD, since all
these infants had biallelic GALC mutations which
had either been previously associated with IKD or
predicted to be deleterious, i.e., frameshift mutations,
in-frame deletions, and splice-site mutations [5].
Psychosine concentrations were elevated in the new-
born DBS of these 5 IKD cases [20, 21]. The infants
with very low leukocyte GALC enzyme activity but
normal psychosine (see above) who have not devel-
oped IKD have at least one mutation previously seen
in a later-onset case [1, 5] or predicted to be “mild”
(often missense mutations) (Table 3) [18–20].
Finally, GALC genotyping is limited in its ability to de-
tect GALC gene deletions [26], and overall, generaliza-
tions about prognosis can be difficult to make from
genotype alone.
As discussed above, there are data indicating that an
elevated blood concentration of psychosine is consistent
with IKD [18–20]. Accordingly, psychosine testing may
have diagnostic value at least when it is found to be ele-
vated. To date, however, psychosine testing has not been
included in routine follow up of at-risk patients identi-
fied through KD-NBS. Furthermore, longitudinal studies
are required to determine if psychosine has value as a
biomarker for determining if HSCT should be initiated
in patients at risk for late onset KD.
In NY, additional neurodiagnostic studies were in-
cluded in the protocol for confirmatory testing [2] at the
SCC: MRI, lumbar puncture to obtain CSF, and nerve
electrophysiology (e.g., nerve conduction studies). While
it is known that in symptomatic Krabbe disease, there
are MRI white matter changes, elevation in cerebro-
spinal fluid protein, and abnormal nerve conduction
studies, these studies are difficult to interpret [27–30] in
the young infant and take time to perform, further
delaying referral for HSCT. Furthermore, HSCT centers
experienced in performing metabolic stem cell trans-
plants have the resources in place to rapidly perform
high quality diagnostic testing. These centers often
prefer to do these studies at their center to facilitate
rapid interpretation. Therefore, though these neurodiag-
nostic studies can help resolve questions about risk of
IKD, it is more important that steps be taken to refer
potential IKD cases to HSCT centers as soon as possible
where these studies can be obtained in parallel with
other preparations for a possibly necessary transplant.
Addressing Question 2: What recommendations
can be made about confirmatory testing strategies?
2a. Recommendation: IKD diagnosis traditionally has
relied on both GALC activity and GALC mutational
testing (with parental phase confirmation). Psychosine
testing can aid in decision making, and because it can
provide rapid results, it should be done by the SCC if it
has not been done earlier. A mechanism must be in
place to guarantee accelerated turn-around time for
these three laboratory tests—GALC enzyme activity,
GALC mutational analysis, and psychosine testing—be-
cause of their importance in determining the risk of true
IKD and the urgency of HSCT. (Grade C).
2b. Recommendation: Since HSCT centers perform
neurodiagnostic studies, such as MRI, lumbar puncture
for CSF protein, and nerve conduction studies, when
evaluating an infant at risk for IKD, the SCC does not
need to perform these studies when assessing IKD risk.
(Grade D).
Question 3. Selection of HSCT centers and timely referral
HSCT can arrest progression of KD through engraftment
of donor-derived, enzyme-producing cells in the bone
marrow, brain, and other organs [1, 4]. Case series show
that HSCT is effective in improving survival and neuro-
logic outcomes in IKD when treatment is started pre-
symptomatically [4, 31, 32]; in these studies, the IKD
diagnosis was established before the 2nd week of life
(even prenatally). Data on long-term outcomes are lim-
ited in this population. Of the two surviving and trans-
planted IKD patients identified through NY’s KD-NBS
program who were transplanted at 31 and 41 days of life,
respectively; both have significant neurologic deficits [6].
A recent report of IKD patients transplanted in the first
2 months of life, suggests those transplanted during their
first 4 weeks of life did better in terms of their overall
survival and function (walking, need for G-tube, among
others) than those transplanted during their 2nd month
of life [8].
Initiating HSCT in an infant diagnosed by NBS with
IKD before 4 weeks of age is challenging. In NY, where
the specialists already have genotyping information avail-
able at the time they see the patient, the referral from
the NBS laboratory may still take over a week due to
delays in sampling and shipping. Additional days are
spent scheduling the specialist appointment and sending
confirmatory testing, by which time the infant may be
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2 weeks old. Table 4 shows the tasks of a metabolic
transplant center preparing an infant with IKD for um-
bilical cord blood transplant which could easily take an-
other 2 weeks. To prevent poor IKD treatment
outcomes from delays in HSCT, the timing of all refer-
rals needs to be closely scrutinized and streamlined. The
patient with IKD identified through KD-NBS in KY
demonstrates that more rapid treatment initiation is
possible [16].
As with any other highly specialized medical proced-
ure, the best results and fewest complications are
achieved at centers that perform the procedure more
frequently. Given the rarity of IKD, outcomes are likely
to be more variable at less experienced HSCT centers
even though these may be geographically closer to the
IKD patient (Table 3). For rare disorders like IKD, the
number of HSCT centers with experience in treating KD
will be small, and IKD families may be presented with
significant geographic and financial barriers to receiving
timely HSCT at one of these centers. This is a serious
consideration when implementing KD-NBS. State pro-
grams must have protocols in place to ensure that
infants diagnosed with IKD will be referred to an experi-
enced HSCT center that is prepared to respond rapidly.
The goal in making these recommendations is to make
sure that the family knows of an IKD diagnosis at a time
when reasonable choices can be made. Accordingly, the
providers in the SCC not only must quickly establish a
probable IKD diagnosis, they also must counsel families
of newborns of all therapeutic options, including refusal
of HSCT.
Addressing Question 3: Given that HSCT treatment
is effective in improving survival and neurologic
outcomes in those with IKD, how can treatment
outcomes be optimized?
3. Recommendation: Expert opinion suggests prompt
referral to a center experienced with KD and other
metabolic transplants could reduce variability in out-
comes. This referral should occur no later than dur-
ing the 3rd week of life (Fig. 1) to ensure initiation of
HSCT during the first 4 weeks of life. To accomplish
this, the SCC initially assessing the referred infant
should already have in place a clear protocol for rapid
referral to an HSCT center. This assumes that prepa-
rations between SCC and HSCT centers have been
made in anticipation of such a referral, with the goal
of minimizing time to initiation of HSCT once a
diagnosis of IKD has been established. (Grade D).
Discussion
KD-NBS remains controversial and there is still much to
learn about the full range of disease presentation and
management [33, 34]. Dimmock, in a recent commen-
tary cites the poor outcomes after HSCT in NY IKD
patients as one reason to reject KD-NBS [35]. In NY
only 4 patients with IKD were treated with HSCT [6],
and while their outcomes were poorer than prior trials
would have suggested [4], the NY IKD cohort was quite
small. Case series of transplanted IKD patients suggest
that better outcomes might be expected if the diagnosis
of IKD was made very early [8] to allow HSCT in the
first month of life. These IKD patients were identified
presymptomatically because of their family history, and
this knowledge allows families and medical providers
valuable time to prepare for treatment. Achieving such
early diagnosis and treatment is clearly more challenging
after newborn screening, yet these burdens have not
been insurmountable. Recently, two children were trans-
ferred (by plane provided by medical aid service) to
Duke University from states (not NY) in order to receive
their transplantation as quickly as possible (J. Kurtzberg,
personal communication). Insurance coverage has not
been a barrier (J. Kurtzberg, personal communication)
since IKD is rare (based on NY data, incidence is 1/
394,000), and very few centers have the expertise to per-
form HSCT in such young Krabbe patients.
Table 4 Schedule of HSCT Center tasks for infants with IKD
requiring HSCT. These are the steps to be taken after: 1) KD-NBS
and confirmatory testing established a diagnosis of IKD, 2)
diagnosis and care options were discussed with the family
1. Refer to transplant center ASAP (DOL 5-6) (Fig. 1)
2. HSCT Center helps to arrange insurance coverage, lodging, admission
for work up
3.Baby admitted to HSCT Center (DOL 7-8):
a. Blood drawn for stat HLA typing (high resolution Class I ABC, Class
II DRB1), and studies, including, blood type, and psychosine
b. Maternal blood for donor screening tests
c. CSF for protein, cell count
d. Neuroimaging tests: MRI brain with DTI
e. Neurophysiological tests: EEG, BAER, VEP, nerve conduction tests
f. Neurology and neurodevelopmental consult
g. Hearing and vision evaluations
h. Echocardiogram to check for PFO or PDA. If present, filter IV lines
to prevent air emboli
i. Physical therapy consultation
j. When HLA typing is available, search for an unrelated cord blood
unit donor, select units (> 4/6 match and > 5×10e7 cells/kg for HLA-
confirmatory typing and GAL-C enzyme levels) to be used for final
unit selection
k. Proceed with insurance/third party payer authorization for
transplantation
l. Place central line and consider G-Tube placement for supplemental
feeding
m. Administer chemotherapy (currently 9 days)
n. Make final cord blood unit selection during chemotherapy
o. Administer transplant (DOL 21+)
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If the goal of NBS is to screen for disorders where
early diagnosis and treatment can significantly change
outcomes, then there was reason to think that IKD
meets this standard. KD-NBS can potentially identify
IKD cases at an age where initiation of HSCT can mark-
edly improve the survival and quality of life of children
with IKD. This treatment currently cannot be considered
a cure and disability is common [4, 8]. This guidance
suggests that outcomes may be improved if greater
awareness and efficiencies are introduced at the level of
the screening laboratory, the SCC, and the HSCT center.
All screening laboratories should have mechanisms for
2nd tier testing (psychosine measurement or some com-
bination of psychosine testing, GALC genotyping, and
30kbDel testing) in place to rapidly identify the rare in-
fants with low GALC activity on DBS who are likely to
develop IKD. Furthermore, results of the 2nd tier testing
should be available by the end of the first week of life. If
the SCC clinicians responsible for confirmatory testing
can receive this information early in the infant’s 2nd
week of life, this allows time to counsel the affected fam-
ily about the disease, treatment options and possible
outcomes, and to discuss the case with the HSCT center
so that a coordinated approach to confirmatory diagnos-
tic testing can be planned if the family chose to pursue a
transplant. This early notification also gives the HSCT
center time to arrange for transfer and identify an ap-
propriate stem cell donor. The choice of HSCT center is
also important and there should be a transparent discus-
sion of the preferred HSCT center(s) to be used when-
ever KD-NBS is considered. These expectations and this
timeline places significant burdens on the newborn
screening program.
We recognize that given the rarity of IKD, there are
only limited data to support these urgent recommenda-
tions. We have relied heavily on the opinions of experts
directly involved in the screening, diagnosis and treat-
ment of IKD. These opinions and the recent literature
about KD-NBS does not constitute a high level of evi-
dence, but this is often the case with rare metabolic dis-
orders [36] These recommendations are meant to help
states or regions considering KD-NBS to understand the
planning, cooperation, and resources that need to be put
in place for successful implementation.
This review has not touched on the issue of those in-
fants who, on confirmatory testing do not have IKD but
based on their low GALC enzyme activity and the pres-
ence of two GALC mutations are presumed to be at risk
for KD, later in life. Counselling the families of those
identified with late-onset KD has been extremely chal-
lenging in NY, the state that has had the longest experi-
ence with KD-NBS. In NY, none of approximately 40
individuals at risk for late-onset KD (with median fol-
lowup of 5 years) have been reported as having any
concerning neurologic symptoms (J. Orsini, personal
communication). The lack of reported late-onset cases
identified by KD-NBS, the documented variability of
late-onset KD progression, and the limited information
about the effectiveness of HSCT in this population, have
contributed to the reluctance of families to come for
routine clinical follow-up [5, 12]. This situation may
change as more is learned about HSCT outcomes in
late-onset KD and the natural history of late-onset KD.
But until then, these guidelines view the primary goal of
KD-NBS as identifying IKD as the “core condition,” with
the late-onset KD cases considered “secondary targets”
or disorders that can be detected in the screening for
core panel conditions [37, 38].
The guidance in this review describes a recommended
response to a possible diagnosis of IKD. The reported
outcomes of IKD patients identified by KD-NBS may
improve in the future if KD-NBS programs stress timely
identification of IKD patients and pay attention to maxi-
mizing efficiency at every stage of the referral process.
NBS programs that add KD to their panels must engage
their state’s specialty care centers, clinical reference la-
boratories, HSCT centers and insurers prior to NBS pro-
gram implementation in order to define the goal of
screening and then develop a plan that ensures smooth
referral of patients and samples without delays. In
addition, long-term follow up programs, including a na-
tionwide and accessible registry, should be established to
more quickly gather a robust data set to support future
evidence based program adjustments.
Conclusions
Key questions about KD-NBS and IKD were addressed
by evaluating new evidence. One recommendation was
that newborn screening laboratories using GALC en-
zyme activity to screen for KD also employ 2nd tier test-
ing to improve the speed and specificity of making an
IKD diagnosis. Screening workflows should be designed
to allow IKD to be identified by the 5th day of life. An-
other recommendation identified confirmatory testing
strategies but emphasized that if IKD was likely (psycho-
sine elevated and/or genotype of known pathogenic sig-
nificance), referral to the HSCT center should be
expedited, even if confirmatory tests were pending or
would have to be conducted at the HSCT center. The
evidence so far indicates that the key to optimal out-
comes in IKD is achieving an early diagnosis and prompt
initiation of stem cell transplantation. These recommen-
dations will help guide programs considering or cur-
rently conducting KD-NBS.
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